| Dr Jeffrey E Steinberg, DPM | |
|
4910 Massachusetts Ave Nw, Suite 315, Washington, DC 20016-4300 | |
| (202) 362-2883 | |
| (202) 362-3330 |
| Full Name | Dr Jeffrey E Steinberg |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 22 Years |
| Location | 4910 Massachusetts Ave Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699769075 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | P01000040 (District Of Columbia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Richard S Cohen Dpm Pa | 1153312400 | 2 |
News Archive
J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.
The YMCA of Greater New York continues to expand its evidence-based, award-winning YMCA's Diabetes Prevention Program, which to-date has helped New Yorkers shed more than two tons of excess weight - or 4,466 pounds - and reduce their risk for developing type 2 diabetes.
Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.
The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.
Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.
› Verified 6 days ago
| Provider Name | Medical Faculty Associates, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1417990581 PECOS PAC ID: 4082528898 Enrollment ID: O20031117000341 |
News Archive
J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.
The YMCA of Greater New York continues to expand its evidence-based, award-winning YMCA's Diabetes Prevention Program, which to-date has helped New Yorkers shed more than two tons of excess weight - or 4,466 pounds - and reduce their risk for developing type 2 diabetes.
Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.
The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.
Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.
› Verified 6 days ago
| Provider Name | Richard S Cohen Dpm Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1023297504 PECOS PAC ID: 1153312400 Enrollment ID: O20040524001167 |
News Archive
J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.
The YMCA of Greater New York continues to expand its evidence-based, award-winning YMCA's Diabetes Prevention Program, which to-date has helped New Yorkers shed more than two tons of excess weight - or 4,466 pounds - and reduce their risk for developing type 2 diabetes.
Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.
The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.
Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.
› Verified 6 days ago
| Provider Name | Whc Physician Group Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1700154226 PECOS PAC ID: 6103093513 Enrollment ID: O20120125000252 |
News Archive
J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.
The YMCA of Greater New York continues to expand its evidence-based, award-winning YMCA's Diabetes Prevention Program, which to-date has helped New Yorkers shed more than two tons of excess weight - or 4,466 pounds - and reduce their risk for developing type 2 diabetes.
Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.
The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.
Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey E Steinberg, DPM 4910 Massachusetts Ave Nw, Suite 315, Washington, DC 20016-4300 Ph: (202) 362-2883 | Dr Jeffrey E Steinberg, DPM 4910 Massachusetts Ave Nw, Suite 315, Washington, DC 20016-4300 Ph: (202) 362-2883 |
News Archive
J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.
The YMCA of Greater New York continues to expand its evidence-based, award-winning YMCA's Diabetes Prevention Program, which to-date has helped New Yorkers shed more than two tons of excess weight - or 4,466 pounds - and reduce their risk for developing type 2 diabetes.
Aneeve Nanotechnologies LLC has been selected to work in the UCLA on-campus Technology Incubator Program at the California NanoSystems Institute. The startup company will conduct early-stage research for the development of a novel hormone sensor/meter for biomedical applications in the areas of infertility and menopause.
The Academy of Nutrition and Dietetics has prepared a request to submit to the Centers for Medicare and Medicaid Services (CMS) to expand coverage of medical nutrition therapy (MNT) for specific diseases, including hypertension, obesity, and cancer, as part of the CMS National Coverage Determination (NCD) Process.
Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.
› Verified 6 days ago
Dr. Arnold S. Ravick, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1145 19th Street, N.w., Suite 409, Washington, DC 20036 Phone: 202-223-0500 Fax: 202-296-2531 | |
Dr. Andrew Lewis Carver, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1040 17th Street Nw, Washington, DC 20036 Phone: 202-296-2424 Fax: 202-318-8197 | |
Foot And Ankle Wellness Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1160 Varnum St Ne Ste 200, Washington, DC 20017 Phone: 202-635-8306 | |
Michael Sean Stempel, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2150 Pennsylvania Ave Nw, Dept. Of Medicine, Washington, DC 20037 Phone: 202-741-3333 | |
Dr. Harold Bruce Glickman, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 5513 Connecticut Ave Nw, Suite 210, Washington, DC 20015 Phone: 202-833-9797 Fax: 202-833-9799 | |
Dr. Barbara Anita Clorey, PA-C Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1350 Connecticut Ave Nw Ste 1250, Washington, DC 20036 Phone: 202-627-1901 | |
Dr. Sheldon I. Laps Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1234 19th St Nw, Suite 610, Washington, DC 20036 Phone: 202-223-9020 Fax: 202-728-0874 |